Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call

DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call.

The live webcast can be accessed at investors.fortrea.com. A replay will be available in the Events and Presentations section of the site following the conclusion of the call.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes